CTOs on the Move

Cumberland Pharmaceuticals

www.cumberlandpharma.com

 
Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products designed to improve quality of care and address unmet medical needs. With a focus on underserved niche markets, including hospital acute care and gastroenterology, we deliver products that serve patients in the U.S. market. Cumberland also makes its products available to patients internationally through select strategic partnerships. We own the worldwide rights to all our brands. While Cumberland`s commercial capabilities are focused on the U.S. market, our business development team is actively pursuing opportunities to make our brands available to patients in markets around the ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Open Door Health

Open Door Health Services has local healthcare clinics in Muncie & Anderson IN. Visit our site to learn about affordable health services. Contact us today!

Quotient Bioresearch

Quotient Bioresearch is a Newtown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intendis Inc

Intendis Inc is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Encounter Telehealth

Encounter Telehealth supports the mental and behavioral health needs of residents in senior living communities across the country. #mentalhealth #telehealth

Jaguar Animal Health

Jaguar Animal Health is a company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals. Our products are designed with a thorough understanding of not only species-specific health issues, but also market practices, the economics of current treatment strategies, competitive dynamics, government initiatives, such as concern for extensive antibiotic usage, and effective channels for new product introductions. In addition to Canalevia™ for dogs and Neonorm™ for preweaned dairy calves, we are developing formulations of these products across multiple animal species and market channels. Our management team has significant experience in gastrointestinal and animal health product development. This experience includes the development of crofelemer for human use, from discovery and preclinical and clinical toxicity studies, including the existing animal studies to be used for Canalevia™ regulatory approvals, through human clinical development. Our team also includes individuals who have prior animal health experience at major pharmaceutical companies, including Ciba-Geigy Corp., now Novartis International AG, SmithKline Beecham Corporation, now GlaxoSmithKline LLC, and the animal health group of Pfizer Inc., now Zoetis Inc.